Xilio Therapeutics (XLO) Cash & Equivalents (2020 - 2026)

Xilio Therapeutics has disclosed Cash & Equivalents across 7 years of filings, most recently posting $150.3 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $150.3 million, up 68.74% year-over-year; the trailing twelve-month figure through Mar 2026 was $150.3 million (up 68.74% YoY), and the FY2025 annual result was $137.5 million, up 148.74% from the prior year.
• Cash & Equivalents came in at $150.3 million for Q1 2026 at Xilio Therapeutics, up from $137.5 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $177.0 million in Q1 2022 to a low of $34.0 million in Q1 2024.
• The 5-year median for Cash & Equivalents is $93.3 million (2023), against an average of $99.8 million.
• Across the five-year window, Cash & Equivalents slumped 63.57% in 2024 and jumped 162.13% in 2025, its largest moves.
• Xilio Therapeutics' Cash & Equivalents stood at $120.4 million in 2022, then sank by 62.87% to $44.7 million in 2023, then grew by 23.68% to $55.3 million in 2024, then soared by 148.74% to $137.5 million in 2025, then advanced by 9.28% to $150.3 million in 2026.
• The last three Cash & Equivalents figures came in at $150.3 million (Q1 2026), $137.5 million (Q4 2025), and $103.8 million (Q3 2025), per Business Quant data.